Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
200 participants
OBSERVATIONAL
2022-04-16
2024-03-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Some previous studies have indicated that the prevalence may be lower than among Westerners, however; studies have also indicated that atrial fibrillation is underdiagnosed.
These studies aim to:
* Estimate the prevalence of AF among Greenlanders in Greenland aged 55 years or older.
* Estimate the prevalence of well-known risk factors among those found to have AF
* Explore the symptoms of those affected by AF in Greenland
* Among part of the participants: estimate the prevalence of autonomic neuropathy as this may cause arrhythmias.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Discerning Symptomatic and Asymptomatic Episodes Pre and Post Radiofrequency Ablation of Atrial Fibrillation
NCT00745706
A Retrospective Register Study to Map the Frequency of Short Duration Atrial Fibrillation (AF) Among All Patients Admitted to Roskilde Sygehus in Denmark in 2010
NCT01502176
Atrial Fibrillation, Prevention and Rehabilitation
NCT06337045
Triggers and Risk Factors for Recurrence of Atrial Arrhythmias With the Use of Long-term Monitoring
NCT05526170
Catheter Cryoablation Versus Antiarrhythmic Drug as First-Line Therapy of Paroxysmal Atrial Fibrillation
NCT01803438
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Risk factors for AF include diabetes, hyperthyroidism, hypertension, obesity, ischemic heart disease (IHD), age and gender with men generally having a higher risk of developing AF.
The current prevalence of cardiac arrhythmias in Greenland is unknown. From 1962 to 1964 12-lead electrocardiograms (ECGs) were performed on 181 adults and only one of these showed AF. A more recent study from 2013 estimating the incidence of ischemic strokes among Greenlanders found that five percent of this study-population had been diagnosed with AF before the incident, while 32.4 % were diagnosed after the incident, suggesting that AF may be underdiagnosed. Comparing the age of the patients to data from Denmark, the authors found that the incidence rate for stroke was higher among almost all younger age groups in Greenland.
Previous studies have shown that ethnicity may influence the risk of developing AF. The genetic profile of the Greenlandic Inuit has already been shown to have a major impact on the risk of developing type 2 diabetes.
Regarding other AF-related risk factors, hypertension is common with a prevalence of app. 40% among men and 32% among women based on self-reported data, and a study comparing data from ECGs performed in 1963 with more current data has shown a rise in the incidence of IHD.
Furthermore, the number of obese people in Greenland is steadily rising and between 1963 and 2008, the proportion of obese people (BMI≥30) increased from 4.0% to 33.2% for men and 8.3% to 24.5% for women between 50 to 69 years.
In conclusion, the risk factors for cardiac arrhythmias are increasing in Greenland and the overall aim of this study is to estimate the prevalence, risk factors, mortality, morbidity and treatment of arrhythmias in Greenland.
Relevance: as mentioned above, this study aims to estimate the prevalence, risk factors, mortality, morbidity and treatment of arrhythmias in Greenland, all of which is currently unknown. By doing this, the study aims to not only improve the treatment rate of arrhythmias, but also lower the prevalence of diseases such as strokes, which are often caused by arrhythmias. By lowering this prevalence, some deaths and cases of disability can be prevented. Furthermore, the investigators hope to assess whether arrhythmias are influenced differently by ethnicity and risk factors such as diabetes in Greenland than in Europe and if patients with certain diseases and/or symptoms have a higher risk of developing arrhythmias and should be monitored more closely.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Main group
All included in the study will offered to participate in:
* ePatch-monitoring
* Blood pressure measurement
* Cardial vagal tone
* Questionnaire-assessment
ePatch
ePatch registers the heart rate continuously when attached to the chest of the participant.
Subgroup
Part of the study-population will be offered to participate in en examination with a SmartPill. The Smartpill measures pressure, pH, temperature and movement in the gut. These measurements gives an indication of the function of the autonomic nervous system (ANS) of the participant. Although measured in the gut, this is relevant as ANS-dysfunction may cause arrhythmias.
Only a subgroup of the study population will be offered to participate due to the cost of this examination.
ePatch
ePatch registers the heart rate continuously when attached to the chest of the participant.
SmartPill
SmartPill is swallowed and passes through the digestive system while sending information to a recording device. The pill is passed in the stool and not reused.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ePatch
ePatch registers the heart rate continuously when attached to the chest of the participant.
SmartPill
SmartPill is swallowed and passes through the digestive system while sending information to a recording device. The pill is passed in the stool and not reused.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Greenlandic ethnicity based on parents' birth place.
* No history of cardiac disease or arrhythmia
Exclusion Criteria
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aalborg University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nadja Albertsen
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nadja Albertsen, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Aalborg University / University of Greenland and Aalborg University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ilisimatusarfik
Nuuk, , Greenland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KVUG 2020-18
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.